Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (121-130 of 304) with videos related to

Pageof 31
Sort By:
JCO Oncology Practice|April 21, 2021
Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal CancerBenjamin W Deschner, Noam A VanderWalde, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2008
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategiesSherry Wolf, Debra Barton, Lisa Kottschade, et al.
Journal of the National Cancer Institute|August 2, 2015
The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical TrialsGita Thanarajasingam, Joleen M Hubbard, Jeff A Sloan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentAxel Grothey, Daniel Sargent, Richard M Goldberg, et al.
Clinical Colorectal Cancer|June 23, 2004
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancersKarin Jordan, Olaf Kellner, Thomas Kegel, et al.
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer: discussionAxel Grothey, Gerald W Prager, Takayuki Yoshino, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|January 10, 2013
Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statementBryan M Clary, Axel Grothey, Scott Kopetz, et al.
Nature Reviews. Clinical Oncology|September 4, 2013
Drug rechallenge and treatment beyond progression--implications for drug resistanceElizabeth A Kuczynski, Daniel J Sargent, Axel Grothey, et al.
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|October 4, 2005
Clinical trial designs for prospective validation of biomarkersSumithra J Mandrekar, Axel Grothey, Matthew P Goetz, et al.
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancerAxel Grothey, Tanios S Bekaii-Saab, Takayuki Yoshino, et al.
Pageof 31

Showing results (121-130 of 304) with videos related to

Sort By:
Pageof 31
JCO Oncology Practice|April 21, 2021
Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal CancerBenjamin W Deschner, Noam A VanderWalde, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2008
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategiesSherry Wolf, Debra Barton, Lisa Kottschade, et al.
Journal of the National Cancer Institute|August 2, 2015
The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical TrialsGita Thanarajasingam, Joleen M Hubbard, Jeff A Sloan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentAxel Grothey, Daniel Sargent, Richard M Goldberg, et al.
Clinical Colorectal Cancer|June 23, 2004
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancersKarin Jordan, Olaf Kellner, Thomas Kegel, et al.
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer: discussionAxel Grothey, Gerald W Prager, Takayuki Yoshino, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|January 10, 2013
Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statementBryan M Clary, Axel Grothey, Scott Kopetz, et al.
Nature Reviews. Clinical Oncology|September 4, 2013
Drug rechallenge and treatment beyond progression--implications for drug resistanceElizabeth A Kuczynski, Daniel J Sargent, Axel Grothey, et al.
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|October 4, 2005
Clinical trial designs for prospective validation of biomarkersSumithra J Mandrekar, Axel Grothey, Matthew P Goetz, et al.
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancerAxel Grothey, Tanios S Bekaii-Saab, Takayuki Yoshino, et al.
Pageof 31